DDInter856 DDInter1802
Unfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated hepar
Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011.
Ticagrelor {u} (Compound) treats {v} (Disease) coronary artery disease
Ticagrelor {u} (Compound) binds {v} (Gene) ABCB1
Ticagrelor {u} (Compound) is included by {v} (Pharmacologic Class) Phenylalanine Hydroxylase Activators
Ticagrelor {u} (Compound) causes {v} (Side Effect) Unspecified disorder of skin and subcutaneous tissue
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Ticagrelor {u} may cause a minor interaction that can limit clinical effects when taken with {v} Nifedipine
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lepirudin
Ticagrelor {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vemurafenib
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Indinavir
Ticagrelor {u} may lead to a major life threatening interaction when taken with {v} Relugolix
Ticagrelor (Compound) treats coronary artery disease (Disease)
Ticagrelor (Compound) binds ABCB1 (Gene)
Ticagrelor (Compound) is included by Phenylalanine Hydroxylase Activators (Pharmacologic Class)
Ticagrelor (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect)
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Clove
Ticagrelor may cause a minor interaction that can limit clinical effects when taken with Nifedipine
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Ticagrelor may lead to a major life threatening interaction when taken with Indinavir
Ticagrelor may lead to a major life threatening interaction when taken with Relugolix